Gynecology Department, Changning Maternity and Infant Health Hospital, East China Normal University, No. 786, Yuyuan Road, Changning District, Shanghai, 200051, China
Auto-generated profile, based on publicly available information
Yu Liu
Gynecology Department, Changning Maternity and Infant Health Hospital, East China Normal University, No. 786, Yuyuan Road, Changning District, Shanghai, 200051, China
Long non-coding RNA HOTAIR has been revealed to participate in the tumorigenesis of various cancers. However, the mechanism of HOTAIR involvement in cervical cancer has not been identified. Hence, this study aimed to explore the oncogenic and chemoresistant roles of HOTAIR in cervical cancer, and its underlying mechanism. RT-PCR, Western blot, and Luciferase assay were employed to determine the relationship of HOTAIR with miR-29b and PTEN and to study the role of HOTAIR in cervical cancer. CCK8 assay, cell migration, and invasion assay were used to reveal the role of HOTAIR in cervical cancer cell proliferation and metastasis. The inhibitory dose of chemotherapeutics was determined by CCK8 assay using probit analysis. HOTAIR was found to bind with miR-29b, and a negative correlation existed between HOTAIR and miR-29b expression in cervical cancer cells. In addition, HOTAIR promoted the migration and proliferation of cervical cancer cell lines HeLa and Siha, showing effects opposite to miR-29b. Further, HOTAIR facilitated the resistance of both HeLa and Siha cells against cisplatin, paclitaxel and docetaxel, whereas miR-29 suppressed the resistance of both cervical cancer cells against the 3chemotherapeutics. In addition, HOTAIR enhanced epithelial-to-mesenchymal transition (EMT), while miR-29b exerted an inhibitory effect on EMT. In cervical cancer cells, miR-29b did not affect promoter methylation of PTEN but regulated PTEN expression by targeting SP1. Transfection of miR-29b mimics led to a significant downregulation of PI3K. HOTAIR promotes chemoresistance by facilitating EMT through the miR-29b/PTEN/PI3K axis in cervical cancer.
24 January 2017 in Experimental and Therapeutic Medicine
It has been demonstrated that various long non‑coding RNAs (lncRNAs) may have key roles in various types of cancer. Clear cell renal cell carcinoma (ccRCC) is the most common subtype of all RCCs, accounting for 70‑80% of all cases. The present study identified a novel lncRNA and investigated its clinical significance and physiological function in ccRCC. The expression pattern of the novel lncRNA LOC389332 in 30 ccRCC tissue samples was examined using reverse‑transcription quantitative polymerase chain reaction. The results demonstrated that LOC389332 expression was markedly lower in ccRCC tissues compared with that in matched adjacent non‑tumor tissues. Of note, downregulation of LOC389332 expression was significantly associated with the tumor American Joint Commission on Cancer stage (P=0.001), Fuhrman grade (P=0.001) and lymph node metastasis (P<0.001). Furthermore, patients with ccRCC with lower levels of LOC389332 expression had a shorter overall survival time than those with higher LOC389332 expression. A gain‑of‑function study was used to evaluate the biological function of LOC389332 in ccRCC and the results suggested that restoration of LOC389332 expression inhibited the growth and migration of the 786‑O and 769‑P cell lines. Therefore, the results of the present study demonstrated that LOC389332 is a novel lncRNA involved in ccRCC progression and may be a potential diagnostic and prognostic biomarker. Ectopic overexpression of LOC389332 may represent a therapeutic strategy for ccRCC.
Ovarian cancer (OV) is characterized by uncontrolled malignant proliferation of ovarian tissue. N-acetyltransferase 10(NAT10) enhances mRNA stability through N4-acetylcytidine (ac4C) modification. This study investigates the oncogenic role of NAT10-mediated ac4C modification in OV and to identify its critical downstream target(s). NAT10 expression was profiled in 18 paired OV and adjacent normal tissues by RT-qPCR and in two OV cell lines (TOV-112D and ES-2) versus a normal control by RT-qPCR and Western blot. ac4C modification was verified by acRIP-qPCR and acRIP-qPCR. Functional assays (CCK-8, Transwell migration and invasion) assessed the impact of NAT10 knockdown. RNA immunoprecipitation (RIP) and dual-luciferase reporter assays mapped the NAT10-NLRP3 interaction and ac4C-dependent regulation of NLRP3 3'UTR stability. Rescue experiments evaluated whether NLRP3 overexpression could reverse the phenotype caused by NAT10 silencing. NAT10 mRNA and protein were significantly up-regulated in OV tissues and cell lines (P < 0.001), with an ROC-derived AUC of 0.865 indicating robust diagnostic potential. Knockdown of NAT10 markedly reduced proliferation, migration, and invasion of OV cells. Mechanistically, NAT10 bound directly to NLRP3 mRNA and augmented ac4C modification within its 3'UTR, thereby extending NLRP3 transcript half-life. Luciferase assays confirmed that mutation of ac4C sites abolished NAT10-mediated regulation. Restoration of NLRP3 expression fully rescued the proliferative and metastatic capacity suppressed by NAT10 depletion. Our findings establish NAT10-mediated ac4C modification of NLRP3 mRNA as a novel epigenetic axis that accelerates OV aggressiveness.Targeting the NAT10-NLRP3 pathway may offer a promising therapeutic avenue for patients with advanced ovarian cancer.